Padeliporfin - Steba Biotech

Drug Profile

Padeliporfin - Steba Biotech

Alternative Names: Padeliporfin di-potassium; Palladium bacteriopheophorbide monolysine taurine; Stakel; TOOKAD Soluble; WST 11

Latest Information Update: 06 Feb 2016

Price : $50

At a glance

  • Originator Steba Biotech
  • Class Antineoplastics; Porphyrins; Small molecules
  • Mechanism of Action Photosensitisers; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Prostate cancer
  • Phase I/II Renal cancer
  • Suspended Choroidal neovascularisation
  • No development reported Cholangiocarcinoma; Non-small cell lung cancer

Most Recent Events

  • 01 Feb 2016 Registered for Prostate cancer in Mexico (IV)
  • 07 Jan 2016 Preregistration for Prostate cancer in European Union (IV)
  • 19 Jun 2013 Steba Biotech completes enrolment in the phase III PCM 301 trial for Prostate cancer in United Kingdom, Belgium, Finland, France, Germany, Italy, Sweden, Denmark, the Netherlands, Spain & Switzerland (NCT01310894)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top